Geranylgeranyl isoprenoids and hepatic Rap1a regulate basal and statin-induced expression of PCSK9
LDL-C lowering is the main goal of atherosclerotic cardiovascular disease prevention, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is now a validated therapeutic strategy that lowers serum LDL-C and reduces coronary events. Ironically, the most widely used medicine to lower c...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2024-03-01
|
| coleção: | Journal of Lipid Research |
| Assuntos: | |
| Acesso em linha: | http://www.sciencedirect.com/science/article/pii/S0022227524000208 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|